Category - Markets

Roth Capital Partners upgraded iRadimed (NASDAQ:IRMD) to “buy” from “neutral” and raised its price target to $12 from $9 after the company reported second quarter results. The stock closed at $9.80 on July 31. iRadimed...

Leerink launched coverage of Axogen (NASDAQ:AXGN) with an “outperform” rating and $22 price target. The stock closed at $15.10 on July 28. “We see Axogen as a unique and sustainable high-growth company, with a unique...

Mackie Research Capital downgraded Intellipharmaceutics International (NASDAQ, TSX:IPCI) to “sell” from “speculative buy” and slashed its price target to $1 from $6 after a FDA advisory committee voted 22-1 against...

Stifel upgraded Tetraphase Pharmaceuticals (NASDAQ:TTPH) to “buy” from “hold” and raised its price target to $15 from $8 after the company reported positive top-line results of the IGNITE4 clinical trial evaluating its...

H.C. Wainwright launched coverage of  Pharming Group NV (AEX:PHARM) with a “buy” rating and €1.50 price target. The stock was recently quoted at €0.45. Pharming is focused on the development of protein therapeutics for...

Roth Capital Partners raised its price target for “buy-rated” Evotec AG (FSE:EVT) to €16 from €5.50, reflecting a review of the company’s partnered pipeline assets. The stock was recently quoted at €11.66. Analyst...

H.C. Wainwright initiated coverage of AzurRx BioPharma (NASDAQ:AZRX) with a “buy” rating and $8 price target. The stock closed at $4.11 on July 24. AzurRx is developing a novel recombinantly produced pancreatic lipase...

Stifel raised its price target for “buy-rated” Reata Pharmaceuticals (NASDAQ:RETA) to $50 from $38 after the company reported statistically significant improvements in kidney function from the Phase 2 portion of its...

H.C. Wainwright initiated coverage of Concert Pharmaceuticals (NASDAQ:CNCE) with a “buy” rating and $20 price target. The stock closed at $16.10 on July 24. Concert’s deuteration technology is a de-risked platform for...

Leerink initiated coverage of Dova Pharmaceuticals (NASDAQ:DOVA) with a “market perform” rating and a $24 price target. The stock closed at $22.75 on July 21. Analyst Geoffrey Porges writes that his rating and valuation...